New guidelines from two leading medical associations suggest that efforts to reduce bad cholesterol should focus on ...

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.

Novartis is performing well despite a recent major patent cliff. Both are attractive dividend stocks, but one has the edge right now, partly because of its valuation. It will lose patent exclusivity ...

Robert F. Kennedy Jr. and a group of personal injury lawyers have long accused Merck & Co. of “disease mongering” to boost ...

The misuse of patents by some of the world’s biggest pharma companies to stifle competition is rarely discussed in global ...

With its drug candidate ARG-007, Argenica seeks a licence to kill the voice of the sceptics – and thrill patients who ...

Pfizer Inc. (NYSE:PFE) was among the stocks on Jim Cramer’s radar on Mad Money as he discussed the upcoming earnings. Cramer ...

As pet owners treat animals like children, the demand for longevity medicine is skyrocketing, creating a bridge for ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

April 20 (Reuters) - Biogen (BIIB.O), opens new tab said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from ...

April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights ‌in Greater China to an experimental immune disease treatment ‌from Chinese biotech firm ...